Immix Biopharma (IMMX) Liabilities and Shareholders Equity (2020 - 2026)
Quarterly results put Liabilities and Shareholders Equity at $95.8 million for Q1 2026, up 381.68% from a year ago — trailing twelve months through Mar 2026 was $236.4 million (up 144.14% YoY), and the annual figure for FY2025 was $104.8 million, up 356.86%.
Immix Biopharma has reported Liabilities and Shareholders Equity over the past 7 years, most recently at $95.8 million for Q1 2026.
- Liabilities and Shareholders Equity reached $95.8 million in Q1 2026 per IMMX's latest filing, down from $104.8 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $104.8 million in Q4 2025 and bottomed at $13.2 million in Q1 2023.
- Median Liabilities and Shareholders Equity over the past 5 years was $20.0 million (2022), compared with a mean of $30.0 million.
- The largest annual shift saw Liabilities and Shareholders Equity crashed 45.78% in 2025 before it surged 381.68% in 2026.
- Over 5 years, Liabilities and Shareholders Equity stood at $14.9 million in 2022, then skyrocketed by 33.65% to $19.9 million in 2023, then increased by 15.17% to $22.9 million in 2024, then skyrocketed by 356.86% to $104.8 million in 2025, then decreased by 8.61% to $95.8 million in 2026.
- Business Quant data shows Liabilities and Shareholders Equity for IMMX at $95.8 million in Q1 2026, $104.8 million in Q4 2025, and $20.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 40.87 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 23.64 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | 95.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95.82 Mn |
| Dec 31, 2025 | 104.84 Mn |
| Sep 30, 2025 | 20.08 Mn |
| Jun 30, 2025 | 15.64 Mn |
| Mar 31, 2025 | 19.89 Mn |
| Dec 31, 2024 | 22.95 Mn |
| Sep 30, 2024 | 25.14 Mn |
| Jun 30, 2024 | 28.84 Mn |
| Mar 31, 2024 | 34.35 Mn |
| Dec 31, 2023 | 19.93 Mn |
| Sep 30, 2023 | 22.47 Mn |
| Jun 30, 2023 | 15.57 Mn |
| Mar 31, 2023 | 13.21 Mn |
| Dec 31, 2022 | 14.91 Mn |
| Sep 30, 2022 | 17.40 Mn |
| Jun 30, 2022 | 19.09 Mn |
| Mar 31, 2022 | 20.02 Mn |
| Dec 31, 2021 | 18.19 Mn |
| Dec 31, 2020 | 539,597.00 |